Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 45Neoplasm Metastasis 6Glioma 6Glioblastoma 6Neoplasms 5Brain Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Sarcoma 3Ovarian Neoplasms 3Liposarcoma 3Diffuse Intrinsic Pontine Glioma 3Astrocytoma 3Recurrence 2Prostatic Neoplasms 2Meningioma 2Medulloblastoma 2Fallopian Tube Neoplasms 2Breast Neoplasms, Male 2Breast Cancer Metastatic 2Venous Thromboembolism 1Triple Negative Breast Neoplasms 1Thymus Neoplasms 1Sarcoma, Synovial 1Rhabdoid Tumor 1Pyloric Stenosis, Hypertrophic 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pinealoma 1Oligodendroglioma 1Non functioning pancreatic endocrine tumor 1Neurofibrosarcoma 1

Interventions

Radiotherapy 6Doxorubicin 5Nivolumab 4pembrolizumab 3Sunitinib 3Ifosfamide 3Gemcitabine 3Docetaxel 3pazopanib 2Radiation Dose Hypofractionation 2Radiation 2Methotrexate 2Ipilimumab 2Cisplatin 2CTLA-4 Antigen 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2tremelimumab 1toripalimab 1temsirolimus 1spartalizumab 1sintilimab 1ribociclib 1regorafenib 1pegfilgrastim 1liposomal doxorubicin 1lentiviral minigene vaccine of COVID-19 coronavirus 1itacitinib 1fludarabine 1eribulin 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Histiocytoma, Malignant Fibrous × ribociclib × Clear all
NCT03009201 2023-08-16

Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery

OHSU Knight Cancer Institute

Phase 1 Completed
16 enrolled
Sarcoma

Fibrosarcoma, Hemangiosarcoma, Liposarcoma, Sarcoma, Disorders of Sex Development, Sarcoma, Synovial, Dermatofibrosarcoma, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡